Document is current
Any future updates will be listed below
-
Authors
Oehler, Sebastian https://orcid.org/0000-0003-2013-7381
Lucaroni, Laura
Migliorini, Francesca
Elsayed, Abdullah
Prati, Luca https://orcid.org/0000-0002-0044-6526
Puglioli, Sara https://orcid.org/0000-0002-4795-7331
Matasci, Mattia https://orcid.org/0000-0003-4221-8852
Schira, Kristina https://orcid.org/0000-0002-6548-331X
Scheuermann, Jörg https://orcid.org/0000-0001-7746-4717
Yudin, Denis https://orcid.org/0000-0002-4103-0543
Jia, Min https://orcid.org/0009-0006-3064-9953
Ban, Nenad https://orcid.org/0000-0002-9527-210X
Bushnell, Dave https://orcid.org/0000-0001-8736-8403
Kornberg, Roger
Cazzamalli, Samuele https://orcid.org/0000-0003-0510-5664
Neri, Dario
Favalli, Nicholas https://orcid.org/0000-0002-6538-7379
Bassi, Gabriele https://orcid.org/0000-0003-0793-5223
- License Information
-
More Information
Article History
Received: 2 September 2022
Accepted: 26 May 2023
First Online: 3 July 2023
Competing interests
: D.N. is co-founder, CEO, CSO and President of the Scientific Advisory Board of Philogen. S.O., L.L., A.E., F.M., S.P., M.M., L.P., S.C., N.F. and G.B. are employed by Philochem AG, the research and development unit of the Philogen. R.K. is member of the Board of Directors Chair and Scientific Advisory Board of NeoTX Therapeutics LTD. D.B. is CSO of the Discovery Division at NeoTX Therapeutics LTD. All other authors do not declare any conflict of interest.
